Harnessing Regeneration in Fertility: Endoret® (PRGF) and the Future of Ovarian Rejuvenation

The role of regenerative medicine in reproductive healthcare is evolving rapidly — and at the forefront of this shift is Endoret® (PRGF), a patented autologous technology developed by BTI Biotechnology Institute. Unlike traditional platelet-rich plasma (PRP), Endoret® is scientifically refined to deliver a pure, activated concentrate of growth factors with no pro-inflammatory content — making it one of the most advanced tools in fertility-focused biologics.

A New Biological Approach to Fertility

Across Europe and increasingly in the UK, fertility clinics are turning to Endoret® (PRGF) as a supportive therapy for women with low ovarian reserve, poor response to stimulation, or unexplained repeated implantation failure. Using a simple blood draw and processing system, Endoret® isolates and activates the patient’s own regenerative proteins — providing a powerful, personalised option to support reproductive success.

Clinical Applications

• Ovarian Rejuvenation

  Intraovarian injection of Endoret® (PRGF) is being explored as a way to stimulate follicular activity, restore perfusion to the ovarian cortex, and promote a more responsive hormonal environment. While still under investigation, early studies and real-world evidence suggest improved ovarian function in some patients previously considered non-responders.

  
  

• Repeated Implantation Failure (RIF)

  Intrauterine infusion of Endoret® has shown potential in improving endometrial thickness and receptivity in women undergoing IVF with thin or unresponsive linings. By delivering pure regenerative proteins directly into the uterine cavity, clinicians may offer a new chance to patients with multiple failed embryo transfers.

Why Endoret® (PRGF)?

Endoret® is not standard PRP. It is a validated, CE-marked system with a controlled process for activating and delivering growth factors. It’s leukocyte-free, reducing inflammation, and supported by a growing body of literature across multiple fields — from maxillofacial surgery to sports medicine and reproductive medicine.

For fertility specialists, this means:

• Consistency and predictability

  
  

• Safety and autologous origin

  
  

• Excellent biocompatibility

  
  

• No additives, no second material

  
  

Distributed in the UK by Sovereign Medical

Sovereign Medical is proud to be the exclusive UK distributor of Endoret® (PRGF) for fertility and women’s health applications. We support fertility clinics with training, regulatory guidance, and clinical implementation across the UK.

As interest in ovarian rejuvenation and biological fertility support continues to grow, we’re here to help you stay at the forefront of this exciting field.

Interested in using Endoret® in your clinic?

Contact us at admin@sovereignmedical.co.uk to arrange a product overview or training session.